The Broadcom MASTERS, the Society for Science’s premier national middle school STEM competition, awards approximately $100,000 in prizes annually, inspiring the next generation of young scientists and engineers. This includes six top awards.

For one family, Regeneron ISEF is tradition. All six siblings have competed in in ISEF for a combined total of 14 years. While many of them are past the age of eligibility, the Dorminys are still finding ways to be involved in ISEF.

Regeneron ISEF 2022 is right around the corner, which means the Society for Science will gain even more amazing alumni. We caught up with 2016 ISEF alum Sidney Chu to learn what he’s been up to and about his plans for the future.

Dr. Roderic Pettigrew and Afton Vechery have joined the Society for Science’s Board of Trustees. They are global leaders in health, medicine and engineering.

A lot has changed since the first Earth Day in 1970. Learn how Society for Science alumni are doing their part to protect our planet.

Gayle Wilson has been named to the Society for Science’s Honorary Board.

The Society for Science celebrates women who are breaking barriers in STEM during Women’s History Month. Learn more about these alumni at the Society’s Notable Alumni website.

The Society for Science celebrates Black leaders in STEM, featuring several science competition alumni.

About Kevin: Kevin is Executive Vice President, Research and Development for Jasper Therapeutics, a biotechnology company developing and commercializing safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. He is also an adjunct professor of medicine at Yale School of Medicine. In previous roles, Kevin served as Chief Medical Officer at NextCure and Vice President and head of antibody clinical development at Incyte. He joined Incyte from AstraZeneca, where he was Senior Medical Director, overseeing global medicines development in oncology. Kevin began his biopharma industry experience at Bristol Myers Squibb, where he led early development programs and was responsible for authoring and managing first-in-human clinical trials.